Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters (ARTEMIS1)

UCB

Status and phase: Terminated; Phase 3

Conditions: Epilepsy

Treatments: Drug: USL261; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01390220

2011-001318-32 (EudraCT Number)

P261-401

Details and patient eligibility

About

The purpose of this study is to examine the safety and effectiveness of USL261 for the outpatient treatment of seizure clusters.

Full description

Qualifying participants underwent an in-clinic administration (Test Dose Phase [TDP]) of two doses of USL261 (intranasal midazolam 5 mg), separated by 10 minutes, in the absence of seizures. Eligible participants were then randomized to USL261 versus Placebo in an outpatient Comparative Phase (CP). When the participant had a qualifying seizure cluster episode, as described in an individualized patient management plan, the participant's caregiver administered the double-blind dose. An open-label USL261 dose could be administered after 10 minutes and up to 6 hours after the double-blind dose, if the participant had persistent or recurrent seizures. Initial participants could not proceed to CP until an independent data safety monitoring board (DSMB) reviewed safety data from at least the first 25 participants in TDP; the DSMB performed additional safety reviews at pre-set intervals based on enrollment.

Enrollment: 292 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Has a competent, adult caregiver who can recognize and observe the subject's seizure cluster episodes

• Has an established diagnosis of partial or generalized epilepsy that includes the following:

  • A documented history of seizure clusters lasting a minimum of 10 minutes
  • Seizure cluster pattern is observable, stereotyped, and recognizably different from the subject's other non-cluster seizure activity (if any)
  • A second seizure in the seizure cluster typically occurring within 6 hours from the time of cluster recognition
  • A seizure cluster pattern composed of multiple (≥ 2) partial or generalized seizures
  • A seizure cluster pattern established > 3 months before Visit 1
  • A frequency of ≥ 3 seizure clusters during the year before Visit 1
  • At least 1 seizure cluster occurring ≤ 4 months before Visit 1
  • Seizure cluster pattern is confirmed by a central reviewer

• Currently on a stable regimen of anti-epileptic drugs (AEDs) with no changes in type of AEDs since Visit 1 and for ≥ 7 days before Visit 2, with or without intermittent use of benzodiazepines at a constant dose

• Weight is 40 kg to 125 kg, inclusive

Exclusion criteria

• Has a neurological disorder that is likely to progress in the next year
• Has severe chronic cardio-respiratory disease
• Has had psychogenic, non-epileptic seizure(s) within the 5 years before Visit 1
• Has a history of their stereotypical seizure cluster progressing to status epilepticus within the 2 years before Visit 1
• Has a history of acute narrow-angle glaucoma.
• Has had active suicidal plan/intent or active suicidal thoughts in the 6 months before Visit 1 or a suicide attempt in the past 5 years
• Currently using a vagal nerve stimulator (VNS) unless the device has been implanted for at least 6 months and the setting stable for 4 weeks before Visit 1

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

292 participants in 2 patient groups

USL261

Experimental group

Description:

intranasal midazolam 5mg

Treatment:

Drug: USL261

Placebo

Experimental group

Description:

Intranasal placebo

Treatment:

Drug: Placebo